October 15, 2014
11:00 am to 12:00 pm EDT

Sponsored by

Webinar Description:

The course topic is a novel antibody selection technology developed by Vaccinex. The technology enables efficient expression of a library of human antibodies in full length IgG format on the surface of vaccinia virus, an enveloped mammalian virus. This technology combines the advantages of virus panning (high throughput), with the advantages of cell sorting (fine tuning of specificity and affinity). The Vaccinia Display technology enables rapid screening of billions of antibody combinations, with the resulting selection of panels of high affinity antibodies. Importantly, with this technology there is a built in selection for antibodies that pass mammalian cell quality control, ensuring that the selected antibodies are efficiently expressed and have favorable developability properties that are well suited for downstream development.

Learning Objectives:

  • Attendees should learn that in vitro selection of full length IgG produced in mammalian cells and displayed on virus is superior to competing platform such as phage, yeast and mice.
  • Attendees should walk away feeling confident that Vaccinex can meet their selection needs from a quality, quantity and timing standpoint.


Ernest S. Smith, PhD

Sr Vice President, Research & Chief Scientific Officer
Vaccinex, Inc.

Cost: No cost!